Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma

BACKGROUND: The United States (US) Expanded Access Program (EAP) to COVID-19 convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease-2019 (COVID-19). While randomized clinical trials...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:medRxiv
Κύριοι συγγραφείς: Senefeld, Jonathon W., Johnson, Patrick W., Kunze, Katie L., van Helmond, Noud, Klassen, Stephen A., Wiggins, Chad C., Bruno, Katelyn A., Golafshar, Michael A., Petersen, Molly M., Buras, Matthew R., Klompas, Allan M., Sexton, Matthew A., Soto, Juan C. Diaz, Baker, Sarah E., Shepherd, John R.A., Verdun, Nicole C., Marks, Peter, van Buskirk, Camille M., Winters, Jeffrey L., Stubbs, James R., Rea, Robert F., Herasevich, Vitaly, Whelan, Emily R., Clayburn, Andrew J., Larson, Kathryn F., Ripoll, Juan G., Andersen, Kylie J., Vogt, Matthew N.P., Dennis, Joshua J., Regimbal, Riley J., Bauer, Philippe R., Blair, Janis E., Wright, Katherine, Greenshields, Joel T., Paneth, Nigel S., Fairweather, DeLisa, Wright, R. Scott, Casadevall, Arturo, Carter, Rickey E., Joyner, Michael J.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Cold Spring Harbor Laboratory 2021
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8043472/
https://ncbi.nlm.nih.gov/pubmed/33851175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2021.04.08.21255115
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια